FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours ner resnonse.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					_			,			1 7									
Name and Address of Reporting Person* Weber Barbara						2. Issuer Name and Ticker or Trading Symbol Revolution Medicines, Inc. [RVMD]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O REVOLUTION MEDICINES, INC. 700 SAGINAW DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 10/01/2020									Officer below)	(give title		Other (: below)	specify		
(Street)	eet) EDWOOD CA 94063						dmer	nt, Date	of Orig	inal Fi	iled (Month/D		6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(Si	tate)	(Zip)																	
		Tab	le I - I	Non-Deri	vativ	e Sec	uriti	es A	cquire	ed, D	isposed o	of, or B	enefic	ially	Owned	i				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yell)						Execution Da		Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			nd 5) Secur Bene Owne		ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common	Stock			10/01/2020				M ⁽¹⁾		2,000	A	\$1.1	\$1.12		808(2)		D			
Common Stock 10/01/20						20			S ⁽¹⁾		2,000	D	\$34.7605 ⁽³⁾		1,8	1,808(2)		D		
Common Stock 10/02/202					020	!0			M ⁽¹⁾		804	A	\$1.12		2,6	2,612 ⁽²⁾		D		
Common Stock 10/02/202						.0			S ⁽¹⁾		804	D	\$36.01	.93(4)	1,8	1,808(2)		D		
Common Stock 10/05/202						:0			M ⁽¹⁾		7,196	A	\$1.1	12	9,0	9,004 ⁽²⁾		D		
Common Stock 10/05/202						.0			S ⁽¹⁾		7,196 D \$36.1		\$36.17	1,808 ⁽²⁾		D				
		T	Table								sposed of , converti				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed tion Date, n/Day/Year)	4. Transa Code 8)				Expiration I (Month/Day		ate	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		De Se (In	. Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	is illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Amo or Num of Title Shar		er						
Stock Option (Right to Buy)	\$1.12	10/01/2020			M ⁽¹⁾			2,000	(6	5)	04/19/2028	Common Stock	2,00	0	\$0.00	26,825		D		
Stock Option (Right to Buy)	\$1.12	10/02/2020			M ⁽¹⁾			804	(€	5)	04/19/2028	Common Stock	804		\$0.00	26,021		D		
Stock Option (Right to Buy)	\$1.12	10/05/2020			M ⁽¹⁾			7,196	(€	5)	04/19/2028	Common Stock	7,19	6	\$0.00	18,825		D		

Explanation of Responses:

- 1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- 2. Includes 1,808 Restricted Stock Units
- 3. The transaction was executed in multiple trades in prices ranging from \$34.26 to \$35.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 4. The transaction was executed in multiple trades in prices ranging from \$36.00 to \$36.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 5. The transaction was executed in multiple trades in prices ranging from \$36.00 to \$36.52, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 6. This option is early exercisable. Twenty-five percent of the total shares subject to the option vested on the first anniversary measured from April 20, 2018 (the "Vesting Commencement Date") and one sixteenth (1/16th) of the shares subject to the option will vest quarterly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each such vesting date.

/s/ Jack Anders, as Attorney-in-10/05/2020 fact for Barbara Weber

^{**} Signature of Reporting Person

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.